Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter
- Company reports strong financial results for 2022 with 27% revenue growth in 2022 and
significantly increased margins - Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as
well as strong market growth - Continued market share gains, strategic mid-term revenue growth at a CAGR of 30%
and further improvement of operating margins targeted
